0001179110-14-012955.txt : 20140815
0001179110-14-012955.hdr.sgml : 20140815
20140815161032
ACCESSION NUMBER: 0001179110-14-012955
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140814
FILED AS OF DATE: 20140815
DATE AS OF CHANGE: 20140815
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCELERON PHARMA INC
CENTRAL INDEX KEY: 0001280600
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SYDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-9200
MAIL ADDRESS:
STREET 1: 128 SYDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kumar Ravindra
CENTRAL INDEX KEY: 0001586835
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36065
FILM NUMBER: 141046616
MAIL ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2014-08-14
0
0001280600
ACCELERON PHARMA INC
XLRN
0001586835
Kumar Ravindra
128 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
VP & Chief Scientific Officer
Common Stock
2014-08-14
4
S
0
2000
29.85
D
33890
D
Common Stock
2014-08-14
4
M
0
5000
5.88
A
38890
D
Common Stock
2014-08-14
4
S
0
7000
30.00
D
31890
D
Option to Purchase Common Stock
5.88
2014-08-14
4
M
0
5000
5.88
D
2019-12-02
Common Stock
5000
10000
D
The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.57 to $30.06, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regrding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.
/s/ John Quisel, as attorney-in-fact for Ravindra Kumar
2014-08-15